Quick Facts

• Used for the long-term maintenance treatment of bronchoconstriction.
• Intended to assist patients with Chronic Obstructive Pulmonary Disease (COPD).
• Appropriate for use in cases of chronic bronchitis and emphysema.

Perforomist (formoterol fumarate) is an approved medication for the long-term, maintenance treatment of airflow obstruction associated with Chronic Obstructive Pulmonary Disease (COPD). It is indicated for use in adult patients who have been diagnosed with conditions such as chronic bronchitis and emphysema.

The role of this treatment is to help sustain open airways, which can facilitate improved breathing over time. This approach aims to control the chronic symptoms of COPD and support patients in managing their overall condition.

It is important to understand that Perforomist is specifically used as a long-term control medication. It is not intended for the prompt relief of sudden or acute breathing difficulties, nor is it indicated for the treatment of asthma.

Official Eligibility Rules for Perforomist

Perforomist (formoterol fumarate) is officially approved by regulatory agencies for use in adult patients as a long-term maintenance treatment for bronchoconstriction associated with Chronic Obstructive Pulmonary Disease (COPD).

Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated and must not be used by patients with a history of hypersensitivity to formoterol fumarate or any product component. Furthermore, the medication is contraindicated for any patient with asthma unless it is being used concurrently with a long-term asthma control medicine, such as an inhaled corticosteroid.

Age-Related and Acute Use Restrictions

Perforomist is not indicated for use in the pediatric population, as safety and effectiveness have not been established in children. The medication must not be used for the relief of acute symptoms or for patients experiencing acutely deteriorating COPD, as it is solely intended for long-term control.

Conditional Use (Use with Caution)

The regulatory label advises caution for patients with specific coexisting conditions, including severe cardiovascular disorders (such as arrhythmias and hypertension), thyrotoxicosis (hyperthyroidism), convulsive disorders, and diabetes. Use in patients with hepatic or renal impairment has not been adequately studied in clinical trials.

Pregnancy and Lactation

Regulatory documents state that it is not known if Perforomist can harm an unborn baby or if the medication passes into human breast milk.

Interactions with other medicines and products

The interaction profile of Perforomist (formoterol fumarate) is defined by pharmacodynamic effects and metabolic pathways, as documented in regulatory labeling. The medicine must not be used in conjunction with other inhaled long-acting beta2-agonists (LABAs), a restriction that avoids excessive sympathetic activity.

Pharmacodynamic Interactions

Co-administration with certain drug classes may lead to altered effects:

• Beta-blockers (Beta-adrenergic receptor antagonists) may inhibit the bronchodilator effect of formoterol. Non-cardioselective beta-blockers may produce severe bronchospasm.
• Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants, and Drugs that prolong the QTc interval require extreme caution due to the potential to potentiate the effect of formoterol on the cardiovascular system.
• Xanthine derivatives, steroids, and non-potassium-sparing diuretics may potentiate the hypokalemic effect associated with adrenergic agonists.

Pharmacokinetic Interactions

Formoterol undergoes biotransformation through specific enzyme systems. It is metabolized by CYP enzymes (including CYP2D6, CYP2C19, CYP2C9, and CYP2A6) and via glucuronidation by UGT enzymes (including UGT1A1, 1A8, 1A9, 2B7, and 2B15). This metabolic profile indicates the potential for altered exposure when co-administered with inhibitors of these specific enzymes.

No specific interactions with food, alcohol, or herbal products are formally documented in the official prescribing information.

The drug acts as a selective agonist that binds to the Beta-2 Adrenergic Receptors (beta2-AR), which are located on the smooth muscle lining the airways. This molecular binding activates the G s protein pathway, which stimulates the enzyme adenylate cyclase to generate cyclic AMP ( cAMP). The cascade subsequently inhibits Myosin Light-Chain Kinase ( MLCK), the enzyme required for muscle contraction. This cellular mechanism shifts the muscle from a contracted state to a relaxed state, modulating the physiological process of airway muscle tone.

Furthermore, the drug's partially lipophilic structure allows it to form a membrane depot in the smooth muscle cell, enabling continuous re-engagement of the receptors. This process contributes to the sustained physiological consequence of muscle relaxation and extended airway patency (bronchodilation).

Official Administration Guidelines

Perforomist (formoterol fumarate) is approved for use exclusively as a long-term maintenance treatment and is strictly prohibited from being used for the immediate relief of acute, sudden breathing symptoms. The treatment protocol is based on a fixed, standardized schedule.

---

Dosing and Administration Schedule

Feature	Official Guideline
Route of Administration	Oral inhalation only using a specific delivery device.
Standard Adult Dose	One unit-dose vial containing 20 micrograms (mcg) of formoterol fumarate per administration.
Dosing Frequency	Twice daily (B.I.D.), administered approximately 12 hours apart, in the morning and evening.
Maximum Daily Dose	The total daily dose must not exceed 40 mcg.
Missed Dose Rule	If a dose is missed, the next dose should be taken at the usual scheduled time; patients must not take two doses to compensate.
Pediatric Use	Safety and effectiveness have not been established for pediatric patients.

---

Procedural and Handling Constraints

The solution is supplied in a sterile, unit-dose vial and must be administered using a standard jet nebulizer connected to an air compressor, as this device is integral to the correct delivery method. The procedural sequence mandates that the entire contents of the vial be squeezed into the nebulizer reservoir. It is explicitly required that the solution not be mixed with any other medications within the nebulizer chamber. Furthermore, any remaining solution in the vial or nebulizer reservoir must be discarded immediately after a single administration to ensure precise monotherapy use.

Evidence for Use in Long-Term COPD Maintenance Treatment

Most research involves Randomized Controlled Trials (RCTs) in adult patients with moderate-to-severe COPD, often continuing stable background treatments. Studies explored outcomes related to physical discomfort and daily functioning. Research reports findings related to short-term changes, including lung function measurements like Forced Expiratory Volume in 1 second ( FEV1).

Study Focus: Lung Function and Symptom Metrics

Researchers monitored patient-reported outcomes such as the Transition Dyspnea Index (TDI) for breathlessness and the St. George’s Respiratory Questionnaire (SGRQ) for daily functioning. Research reports patterns observed in these metrics; however, findings apply only to the studied populations and do not offer individual predictions.

---

Overview of Research Structure

Studies included placebo-controlled trials and those that examined the nebulized solution against other forms of the active ingredient, such as dry powder inhalers, to compare delivery effects. Research also assessed the medication when added to a patient's existing maintenance therapy for COPD.

---

Long-Term Evidence and Evidence Gaps

Research includes longer-duration studies extending up to approximately one year, often conducted as post-marketing commitment studies. These trials monitored the incidence of COPD-related events (e.g., hospital stays).

A major limitation is that studies excluded patients dealing with acute, sudden worsening of their symptoms, meaning research does not cover its use in episodes of acute or disruptive changes. Long-term trials were primarily designed to assess noninferiority (not worse than) against a placebo for clinical events, not to show superiority for efficacy outcomes over the full year. Data for certain groups, such as those with very severe COPD, remain insufficient.

Key Studies & References Randomized, Controlled Trial of Formoterol Fumarate Inhalation Solution vs. Dry Powder Inhaler in Moderate-to-Severe COPD (Study for Comparative Efficacy)

Common questions about Perforomist (FAQ)

Q: Can I use a different device to inhale the solution besides a nebulizer?

According to official product information, Perforomist inhalation solution is only to be administered using a standard jet nebulizer connected to an air compressor. The safety and effectiveness of the solution have not been established when used with any other type of inhalation device. It is important to follow the specific delivery method required by the product's official labeling.

---

Q: How quickly does Perforomist start working?

Studies and official information indicate that this medication has a rapid onset of action in the airways. While regulatory documents do not specify an exact number of minutes for the initial effect, the medication is designed for long-term control and not for immediate rescue. The maximum benefit for long-term breathing maintenance is achieved over time as part of the prescribed treatment schedule.

---

Q: Can I use Perforomist if I have kidney or liver disease?

Official information states that the effects of the drug in patients with severe hepatic (liver) or renal (kidney) impairment have not been adequately studied in clinical trials. This means there is insufficient data regarding how the body handles the drug, or its pharmacokinetics, in these specific groups. Caution is advised for patients with certain pre-existing medical conditions, as noted in the product's official prescribing information.

---

Q: Can I mix other medicines with Perforomist in the nebulizer?

No. The safety, effectiveness, and physical compatibility of the solution when mixed with any other drugs in the nebulizer chamber have not been established according to regulatory documentation. Patients are advised to use the medication exactly as prescribed and administer the entire contents of the vial without mixing it with any other substance.

---

Q: What is the mechanism of action that causes my airways to relax?

The medication works on specific receptors in your lungs, called Beta-2 Adrenergic Receptors. When the drug binds to these receptors, it causes the smooth muscles that surround your airways to relax, leading to the widening of the air passages—a process known as bronchodilation. This targeted action is intended to provide sustained relaxation of the airways, contributing to long-term symptom management.

---

Q: Is it safe for children to use Perforomist?

The official product information states that the safety and effectiveness of this medication have not been established in pediatric patients (children). Therefore, this medication is only approved for long-term maintenance treatment in adults with COPD. As a result, the medication is not indicated for use in this population based on current regulatory standards.

How to Store and Dispose of Perforomist

Perforomist Inhalation Solution must be stored primarily in a refrigerator at temperatures between 36 to 46 F (2 to 8 C). The unit-dose vials must remain in their original protective foil pouch to ensure they are shielded from light and heat, and they must not be frozen.

Room Temperature Storage and Stability

As an alternative, the medication may be stored at room temperature (68 to 77 F) for a period of up to three months (90 days). If stored outside of refrigeration, the product must be discarded after 90 days or by the expiration date, whichever is sooner. Once a foil pouch is opened, the vial must be used immediately, and any contents remaining in a partially used container must be discarded.

Disposal and Child Safety

Perforomist must be kept out of the reach of children at all times. Unused or expired medication should be disposed of by following guidance from a pharmacist or a healthcare professional on drug take-back programs.